More on Mast Therapeutics: Starts Phase II trial for lower-limb ischemia

|About: Mast Therapeutics, Inc. (MSTX)|By:, SA News Editor

Mast Therapeutics (MSTX) initiates a Phase II study of MST-188 in patients with acute lower-limb ischemia, which is a complication of peripheral arterial disease that can lead to a limb being amputated and even death. (PR)

Shares are +8.3%.

Q4 Earnings